SubHero Banner

Delstrigo® (doravirine/lamivudine/tenofovir disoproxil fumarate) – Expanded indication

September 19, 2019 - The FDA approved Merck’s Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate [TDF]), as a complete regimen for the treatment of human immunodeficiency virus (HIV)-1 infection in adult patients to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Delstrigo.

Download PDF